ibuprofen

Overview

Ibuprofen is a propionic acid-derived non-steroidal anti-inflammatory drug (NSAID) widely used for its analgesic, antipyretic, and anti-inflammatory properties. It exerts its pharmacological effects primarily through reversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the biosynthesis of prostaglandins and thromboxanes involved in pain signaling, fever induction, and inflammatory cascades. Available in numerous formulations — including immediate-release tablets, lysinate salts, and sustained-release compositions — ibuprofen occupies a central role in both prescription and over-the-counter (OTC) pain and fever management, with non-prescription use typically capped at a maximum daily dose of 1,200 mg. Beyond its classical analgesic indication, ibuprofen has attracted sustained scientific interest for its potential utility in oncology, infectious disease, drug delivery, and environmental monitoring, positioning it as a molecularly versatile compound across multiple biomedical domains.

As a small-molecule NSAID, ibuprofen belongs to the same pharmacological class as indomethacin, naproxen, Diclofenac, ketoprofen, and mefenamic acid — agents with which it is frequently compared in pharmacokinetic, ecological, and clinical studies. Its broad tissue distribution and relatively short half-life make formulation optimization an active area of pharmaceutical research, while its widespread consumption and incomplete environmental metabolism have established it as a prototypical pharmaceutical micropollutant of global concern.

Recent Publications Summary

Recent studies have focused on ibuprofen as both a formulation target and a component of combination therapies, with several groups aiming to improve its dosing convenience, release profile, and local delivery. A biphasic modified-release 400 mg immediate-release/sustained-release tablet was developed to address ibuprofen’s short half-life and need for frequent dosing; in single-dose and multiple-dose crossover studies, the new formulation showed equivalent steady-state total, peak, and minimum exposure to a reference immediate-release product, and its food effect was also evaluated 42374602Jun. In a separate pharmacokinetic and modeling study, an immediate-release/sustained-release 400 mg bi-layer tablet maintained plasma concentrations above predefined onset and duration thresholds for 8 hours, extending therapeutic coverage compared with other immediate-release formulations 41720357Feb.

Other publications examined ibuprofen in advanced oral dosage forms and manufacturing platforms. Amorphous solid dispersions of ibuprofen with hydroxypropyl methylcellulose acetate succinate were produced by hot-melt extrusion and then converted into solid dosage forms by fused deposition modelling 3D printing or conventional direct compression; the work confirmed ibuprofen amorphisation and showed that 3D-printed products initially dissolved more slowly, although print design could be adjusted to improve performance 42217813May. Semi-solid extrusion 3D printing using milk formula as the main excipient was also used to make pediatric chewable dosage forms containing ibuprofen, with dose accuracy scaling linearly with print weight and dissolution data showing a modest improvement in ibuprofen release from the milk matrix 42031026Apr. In manufacturing research, membrane percrystallization was used to crystallize ibuprofen with high yield and purity, producing stable Form I crystals with improved flowability and without a separate drying step 41941942Apr.

Ibuprofen was also studied in combination products and local delivery systems. A validated eco-friendly HPTLC method was developed for simultaneous determination of erdosteine, ibuprofen, and pseudoephedrine in a pharmaceutical combination intended for upper respiratory tract infection symptom relief 42303778Jun. For osteoarthritis, ibuprofen and resveratrol were co-loaded into mesoporous silica nanoparticles and incorporated into thermoresponsive injectable hydrogels for intra-articular delivery; the formulations showed rapid ibuprofen release, sustained resveratrol release, and beneficial effects in a papain-induced rat model 41839392Mar. In infectious keratitis, topical levofloxacin plus ibuprofen eye drops were tested in rats with Staphylococcus aureus-induced disease, and the combination produced the lowest expression of inflammatory mediators and metalloproteinases among the treated groups 42031955Apr.

Additional studies explored broader biomedical and environmental contexts for ibuprofen. In a lung cancer organoid platform used to study resistance to third-generation EGFR-TKIs such as osimertinib, Connectivity Map screening identified ibuprofen as a candidate that could enhance anti-tumor activity 41740831Feb. In water-quality research, graphene-based electrochemical sensors showed that ibuprofen generated comparable responses to other oxidizable contaminants under optimized electro-Fenton conditions, supporting its use as part of a broader contaminant burden assessment 42060697Apr. Ecotoxicological work also included ibuprofen among pharmaceutical and personal care products evaluated for chronic effects in plant and earthworm bioassays, although the abstract emphasized stronger effects from hazelnut shell exposure than from the pharmaceutical contaminants 41965162Apr.

What Changes, What Holds

1. Modified-release designs extend ibuprofen coverage without changing its core role
REINFORCES Biphasic and bi-layer formulations do not alter the established account of ibuprofen as a short-half-life NSAID; they sharpen the practical implication that formulation engineering can partly compensate for frequent dosing. The new work supports the baseline emphasis on sustained-release optimization and shows that exposure can be matched or prolonged while preserving therapeutic coverage 42374602Jun41720357Feb.

2. Advanced manufacturing can reshape ibuprofen dosage forms, but not its pharmacology
METHOD Hot-melt extrusion, 3D printing, and membrane percrystallization mainly change how ibuprofen is made and delivered, not what it is known to do. These studies add to the baseline’s formulation-optimization theme by showing that amorphisation, print architecture, and crystallization control can be used to tune dissolution, dose accuracy, and solid-state properties 42217813May41941942Apr.

3. Combination and local-delivery studies broaden ibuprofen’s application space without displacing its established uses
NEW DIRECTION Co-formulation with other agents and intra-articular or ophthalmic delivery extend ibuprofen into symptom-combination and local-treatment settings that the Overview does not specifically cover. That broadens its biomedical reach, but it does not contradict the baseline analgesic/anti-inflammatory account; instead, it suggests the drug is being repurposed into more targeted delivery contexts where local inflammatory control may matter 42303778Jun41839392Mar.

4. Ibuprofen is being explored as a candidate in oncology and environmental sensing, but these roles remain exploratory
NEW DIRECTION Screening work in lung-cancer organoids points to a possible adjunctive anti-tumor role, while sensor studies use ibuprofen as one analyte among oxidizable contaminants. Neither role is part of the established account, so these findings add new directions rather than revise the drug’s core NSAID identity. The oncology signal is especially preliminary and would need mechanistic and in vivo validation before it could be treated as more than hypothesis-generating 41740831Feb42060697Apr.

Overview update candidates: modified-release formulations that maintain or extend therapeutic exposure; advanced manufacturing approaches for ibuprofen dosage forms; exploratory local-delivery; combination; oncology; and environmental-sensing applications.